Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background And Aims: The molecular, endoscopic, and histological features of IBD-associated CRC differ from sporadic CRC. The objective of this study was to describe the prevalence, clinical features, and prognosis of IBD-associated CRC compared to patients with sporadic CRC in a US statewide population-based cohort.

Methods: All newly diagnosed cases of CRC between 1996 and 2011 were obtained from Utah Cancer Registry. IBD was identified using a previously validated algorithm, from statewide databases of Intermountain Healthcare, University of Utah Health Sciences, and the Utah Population Database. Logistic regression was performed to identify risk factors associated with IBD-associated cancer and Cox regression for differences in survival.

Results: Among 12,578 patients diagnosed with CRC, 101 (0.8%) had a prior history of IBD (61 ulcerative colitis and 40 Crohn's disease). The mean age at CRC diagnosis was greater for patients without IBD than those with IBD (67.1 vs 52.8 years, P < 0.001). Individuals with IBD-associated CRC were more likely to be men (odds ratio [OR] 1.90, 95% CI 1.23-2.92), aged less than 65 years (OR 6.77, 95% CI 4.06-11.27), and have CRC located in the proximal colon (OR 2.79, 95% CI 1.85-4.20) than those with sporadic CRC. Nearly 20% of the IBD-associated CRCs had evidence of primary sclerosing cholangitis. After adjustment for age, gender, and stage at diagnosis, the excess hazard of death after CRC diagnosis was 1.7 times higher in IBD than in non-IBD patients (95% CI 1.27-2.33).

Conclusions: The features of patients with CRC and IBD differ significantly from those without IBD and may be associated with increased mortality.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10620-016-4435-4DOI Listing

Publication Analysis

Top Keywords

ibd-associated crc
8
sporadic crc
8
crc
7
colorectal cancer
4
cancer inflammatory
4
inflammatory bowel
4
bowel diseases
4
diseases population-based
4
population-based study
4
utah
4

Similar Publications

Colorectal cancer (CRC) is a serious complication of inflammatory bowel disease (IBD), significantly contributing to increased mortality and health care burden. Although advances in IBD management have led to a decline in CRC incidence, it remains a major clinical concern. Recent breakthroughs in advanced imaging, molecular diagnostics, and artificial intelligence are poised to revolutionize precision medicine in IBD-associated CRC, potentially reducing neoplastic risk and improving patient outcomes.

View Article and Find Full Text PDF

Inflammatory bowel disease (IBD)-associated colorectal cancer (CRC) is a serious global health issue. Owing to the successful mimicking of the entire process of CRC induced by IBD, azoxymethane (AOM) and dextran sulfate sodium (DSS)-induced colitis-associated cancer (CAC) animal models have been widely used to study the carcinogenic mechanisms of IBD-associated CRC and aid in the discovery of new candidate target drugs for CRC treatment. This article summarizes the molecular characteristics and mechanisms of the AOM/DSS-induced CAC animal model and reports the effects and mechanisms of dietary active ingredients such as phenolics, flavonoids, terpenes, polysaccharides, alkaloids, and other food extracts in the prevention and treatment of AOM/DSS-induced CAC in preclinical trials.

View Article and Find Full Text PDF

Colorectal cancer (CRC) remains a major threat to health worldwide, partly due to the lack of effective treatments targeting the transition from inflammatory bowel disease (IBD) to malignancy. Astragaloside IV (AS-IV) is a major bioactive component from the traditional herb , and it has strong immunomodulatory and gastrointestinal protective effects. In this review, we evaluate the therapeutic potential and mechanisms of AS-IV in addressing the three hallmark pathological phases of colorectal cancer development: IBD-related inflammation, the transition from inflammation to cancer, and IBD-associated colorectal cancer (IBD-CRC).

View Article and Find Full Text PDF

Inflammatory bowel disease (IBD)-associated colorectal cancer (CRC) remains a significant clinical challenge due to its link with chronic inflammation and the inherent limitations of current prevention and surveillance strategies. The cGAS-STING pathway has emerged as a key player in the immune regulation of inflammation-driven carcinogenesis, demonstrating both protective and pathogenic roles. This review examines the contrasting roles of the cGAS-STING signaling pathway in intestinal inflammation and colitis-associated cancer (CAC), emphasizing its promise as a target for cancer prevention strategies.

View Article and Find Full Text PDF

Inflammatory bowel disease (IBD), comprising ulcerative colitis (UC) and Crohn's disease (CD), is a chronic condition marked by persistent intestinal inflammation of unknown etiology. Disease onset involves genetic predisposition and environmental factors that disrupt the intestinal immune homeostasis. The intestinal microbiome and immune response play pivotal roles in disease progression.

View Article and Find Full Text PDF